Patient P-02125
Therapy response
Improving
Tolerance
Deteriorating
GI state
Deteriorating
Inflammatory state
Stable
Nutritional resilience
Declining
Discontinuation risk
79%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S14
- Day 70 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 71 SC-12 recommended — Supportive Compound SC-12
- Day 72 Patient declined — Not now
- Day 80 GI-04 recommended — GI Support Protocol GI-04
- Day 81 Patient accepted — Started GI-04 in the companion
- Day 83 ME-01 recommended — Monitoring Escalation ME-01
- Day 84 Patient accepted — Started ME-01 in the companion
- Day 87 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
- Day 89 GI symptom burden −37% vs expected — GI Support Protocol GI-04
- Day 95 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 70.
Primary contributors, last 14 days
- Toxicity+16
- GI instability+8
- Nutritional resilience-4
- Inflammatory activity+2
- Treatment adherence-2
What helped?
- Supportive Compound SC-12Day 71Declined by patient
- GI Support Protocol GI-04Day 80Result: symptom burden −37%
- Monitoring Escalation ME-01Day 83Result: deterioration detected before clinical escalation
LIFE OS recommendation
Dietary Support Protocol NP-02
58%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 64% showed improvement
- median effect visible after 10 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 29/100
- Daily logFibre intake low in recent food logs
- Mucosal barrier integrity ↓50
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 48 and rising
- Inflammatory signalling ↑40
- BloodInflammatory load index 52
- WearableHRV 23 ms, trending down
- Autonomic recovery ↓25
- WearableResting HR 83 bpm
- Drug metabolism and exposure ↑20
- BloodToxicity index 56
DNA
Fictional pharmacogenomic panel
- CYP2D6 Intermediate metabolizerExpected exposure
- GLP1R rs6923761 AAltered receptor sensitivity
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 2.6 · butyrate capacity 29/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 20 ms
- Sleep
- 7.0 h
- Steps
- 5,972
- Resting HR
- 84 bpm
Daily log: GI score 48, nutritional resilience 46, adherence 45.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.